Malignant Odontogenic Neoplasm
NCI Definition: A rare neoplasm arising from tooth-forming tissues. It occurs in the maxillofacial skeleton or the gingiva. Symptoms include swelling, pain, bleeding, mobility of affected teeth, and oral mucosa ulcerations. It may metastasize to lymph nodes and distant anatomic sites early. 
Malignant odontogenic neoplasms most frequently harbor alterations in EWSR1, ATF1, SYNE1, RICTOR, and PRKDC .
EWSR1 Fusion, EWSR1-ATF1 Fusion, SYNE1 R5410Q, RICTOR Mutation, and RICTOR L212F are the most common alterations in malignant odontogenic neoplasm .
There are 2 clinical trials for malignant odontogenic neoplasm, of which 2 are open and 0 are completed or closed. Of the trials that contain malignant odontogenic neoplasm as an inclusion criterion, 2 are phase 2 (2 open).
Ipilimumab, nilotinib, and nivolumab are the most common interventions in malignant odontogenic neoplasm clinical trials.
Significant Genes in Malignant Odontogenic Neoplasm
CD274 is an inclusion eligibility criterion in 1 clinical trial for malignant odontogenic neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and malignant odontogenic neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.